Coherus Q3 Revenue Misses; Cuts ~30% of Staff, Narrows Pipeline to Esophageal Cancer
CHRS is trading near its 52-week low of $0.732 (9.0% above the low).
Summary
Coherus reported Q3 revenue of $14.274M, missing estimates, and announced a strategic prioritization plan that cuts headcount ~30% and focuses tagmokitug on esophageal cancer, lowering quarterly core cash burn by $6-7M.
Key Events · Earnings and Guidance · CHRS
-
Q3 Revenue Misses Consensus
Net revenue came in at $14.274 million versus roughly $16 million expected, an ~11% miss, though up 25% from $11.2 million in Q3 2025.
-
~30% Headcount Reduction
The strategic prioritization plan right-sizes the organization, cutting headcount by approximately 30% and lowering core cash burn by $6 million to $7 million quarterly.
-
Pipeline Narrowed to Esophageal Cancer
Tagmokitug/toripalimab development is focused on esophageal cancer with plans for an expedited path, initially second-line; other tagmokitug-toripalimab cohorts are deprioritized.
-
Cash Runway Still Tight
Cash, cash equivalents and marketable securities totaled $83.6 million at September 30, 2026, down from $172.1 million at December 31, 2025, against a $38.9 million Q3 net loss from continuing operations.
Analysis · CHRS · Life Sciences
The Q3 revenue miss ($14.274M vs ~$16M consensus) is being met with a real restructuring: about 30% of headcount goes, tagmokitug development narrows to esophageal cancer, and core cash burn drops by $6-7M per quarter. That lowers the LOQTORZI revenue needed to cover core burn to $25-30M quarterly from the prior $30-35M guide — meaningful because LOQTORZI did $14.0M this quarter. With $83.6M of cash against a $38.9M quarterly net loss, the runway math still points to more capital raises; the $50M ATM with Leerink filed in August is the likely source.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CHRS was trading at $0.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $126.3M. The 52-week trading range was $0.73 to $2.62. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.